Because of its proximal role in BCR signaling in CLL cells, the effects of Lck inhibition should be similar to idelalisib and ibrutinib and reduce lymphadenopathy and promote lymphocytosis. Here, BCR is linked to B-cell chronic lymphocytic leukemia.